ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer

A new phase 3 trial analysis found that daraxonrasib, an oral targeted therapy, improved survival for patients with advanced metastatic pancreatic cancer across various RAS mutation statuses and chemotherapy treatment groups. The drug was FDA approved in August 2026 for patients with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are unsuitable for multiagent systemic therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 24 Oct 2026.